<DOC>
	<DOCNO>NCT01599871</DOCNO>
	<brief_summary>The main objective study determine effect low-dose oral theophylline add combination treatment long-acting Î²-agonist ( LABA ) inhale corticosteroid ( ICS ) patient severe Chronic Obstructive Pulmonary Disease ( COPD ) rate exacerbation define increase symptom require change medication ( antibiotic and/or systemic glucocorticoid ) hospitalisation . DESIGN : Phase III multicenter , randomize , placebo-controlled , double blind , parallel , prospective study . Patient recruit hospitalisation due COPD exacerbation randomise time discharge receive theophylline 100 mg placebo top combination therapy inhaled corticosteroid long-acting beta agonist . The rate exacerbation determine every three month one year follow-up . Cl inic visit : every 3 month ( total number clinic visit = 4 ) . In , follow information obtain : - Number/severity exacerbation hospitalisation since last clinic visit - Compliance side effect - Blood sample - Plasma level theophylline - Sputum ( induce ) - MMRC - SGRQ - Forced spirometry + inspiratory capacity - At begin end study - 6MWT - BMI - BODE</brief_summary>
	<brief_title>Low-dose Theophylline Anti-inflammatory Enhancer Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Participant willing able give inform consent participation study . Ability understand study procedure comply entire length study . Any gender . No contraception require neither pregnancy expect range age Age &gt; 45 year Smoking history &gt; 10 packyears ( current exsmokers ) Clinical diagnosis COPD Presence severe airflow obstruction force spirometry ( FEV1/FVC &lt; 0.7 postBD FEV1 &lt; 50 % reference value ) stag GOLD III IV Diagnosis COPD exacerbation discharge . Presence history chronic respiratory disease ( asthma , bronchiectasis , TB lesion ) Cancer Heart failure Pregnancy , risk pregnancy Other inflammatory disease Previous treatment theophylline For drug study : allergy/sensitivity study drug ingredient . Current drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Inability unwillingness individual legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>COPD</keyword>
</DOC>